Molgramostim Open-label clinical trials

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

This study looks at a new inhaled medicine, molgramostim, for a rare lung condition called autoimmune pulmonary alveolar proteinosis (aPAP). We want to see if it helps patients better than a dummy treatment. After 48 weeks, everyone gets the active medicine.